Open Access
Antiangiogenic therapies for malignant pleural mesothelioma
Seiji Yano1,Qi Li1,Wei Wang1,Tadaaki Yamada1,Shinji Takeuchi1,Emiko Nakataki1,Hirokazu Ogino1,Hisatsugu Goto1,Yasuhiko Nishioka1,Saburo Sone1
Division of Medical Oncology, Cancer Research Institute, Kanazawa University. Kanazawa, Ishikawa 920-0934, Japan.
DOI: 10.2741/3716 Volume 16 Issue 2, pp.740-748
Published: 01 January 2011

Malignant pleural mesothelioma (MPM), arises from the mesothelial cells, is difficult to be diagnosed at an early stage, and is refractory to conventional chemotherapy and radiotherapy. Therefore, the establishment of novel effective therapies is necessary to improve the prognosis for many patients with this disease. Recent studies have demonstrated that angiogenesis plays a significant role in MPM progression, suggesting the importance of tumor vessels as therapeutic targets. To explore molecular pathogenesis and evaluate the efficacy of vascular targeting therapy in MPM, we developed orthotopic implantation SCID mouse models of MPM. We found that selective VEGF inhibitors were effective only in the treatment of high-VEGF-producing MPM models. On the other hand, multiple kinase inhibitor E7080, with inhibitory activity against various angiogenic cytokine receptors, suppressed the progression and prolonged survival of both high-VEGF-producing and low-VEGF-producing MPM models. Further understanding of the functional characteristics of tumor angiogenesis may be essential to improve targeting therapies in MPM. In this review, we introduce current status of clinical strategies and novel therapeutic approaches against angiogenesis in MPM.

Share and Cite
Seiji Yano, Qi Li, Wei Wang, Tadaaki Yamada, Shinji Takeuchi, Emiko Nakataki, Hirokazu Ogino, Hisatsugu Goto, Yasuhiko Nishioka, Saburo Sone. Antiangiogenic therapies for malignant pleural mesothelioma. Frontiers in Bioscience-Landmark. 2011. 16(2); 740-748.